Literature DB >> 33021036

The characteristics and roles of β-TrCP1/2 in carcinogenesis.

Yanli Bi1,2, Danrui Cui1,2, Xiufang Xiong2,3, Yongchao Zhao1,2.   

Abstract

β-transducin repeat-containing protein (β-TrCP), one of the well-characterized F-box proteins, acts as a substrate receptor and constitutes an active SCFβ-TrCP E3 ligase with a scaffold protein CUL1, a RING protein RBX1, and an adaptor protein SKP1. β-TrCP plays a critical role in the regulation of various physiological and pathological processes, including signal transduction, cell cycle progression, cell migration, DNA damage response, and tumorigenesis, by governing burgeoning amounts of key regulators for ubiquitination and proteasomal degradation. Given that a variety of β-TrCP substrates are well-known oncoproteins and tumor suppressors, and dysregulation of β-TrCP is frequently identified in human cancers, β-TrCP plays a vital role in carcinogenesis. In this review, we first briefly introduce the characteristics of β-TrCP1, β-TrCP2, and SCFβ-TrCP ubiquitin ligase, and then discuss SCFβ-TrCP ubiquitin ligase regulated biological processes by targeting its substrates for degradation. Moreover, we summarize the regulation of β-TrCP1 and β-TrCP2 at multiple layers and further discuss the various roles of β-TrCP1 and β-TrCP2 in human cancer, functioning as either an oncoprotein or a tumor suppressor in a manner dependent of cellular context. Finally, we provide novel insights for future perspectives on the potential of targeting β-TrCP1 and β-TrCP2 for cancer therapy.
© 2020 Federation of European Biochemical Societies.

Entities:  

Keywords:  CRL; Cullin-RING ligase; F-box protein; SCF; tumorigenesis; β-TrCP

Year:  2020        PMID: 33021036     DOI: 10.1111/febs.15585

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  7 in total

1.  A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy.

Authors:  Iqra Bano; Moolchand Malhi; Min Zhao; Liviu Giurgiulescu; Hira Sajjad; Marek Kieliszek
Journal:  3 Biotech       Date:  2022-03-29       Impact factor: 2.406

2.  YAP promotes the activation of NLRP3 inflammasome via blocking K27-linked polyubiquitination of NLRP3.

Authors:  Dan Wang; Yening Zhang; Xueming Xu; Jianfeng Wu; Yue Peng; Jing Li; Ruiheng Luo; Lingmin Huang; Liping Liu; Songlin Yu; Ningjie Zhang; Ben Lu; Kai Zhao
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

3.  P90 ribosomal S6 kinase confers cancer cell survival by mediating checkpoint kinase 1 degradation in response to glucose stress.

Authors:  Ying Ma; Danrui Cui; Linchen Wang; Yue Wang; Fei Yang; Hui Pan; Longyuan Gong; Minrun Zhang; Xiufang Xiong; Yongchao Zhao
Journal:  Cancer Sci       Date:  2021-11-03       Impact factor: 6.716

Review 4.  The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression.

Authors:  Lu Xia; Jingyun Chen; Min Huang; Jie Mei; Min Lin
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

5.  CircRNA expression profile and potential role of hsa_circ_0040039 in intervertebral disc degeneration.

Authors:  Sheng Huang; Junlong Zhong; Qihua Qi; Gangan Liu; Ming Gong
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

6.  Activation of the β‑TrCP/IκBα/inflammation axis limits the sensitivity of liver cancer cells to neddylation inhibition.

Authors:  Haojun Xiong; Dandan Zheng; Ying Liu; Lihai Ma; Lingzhan Meng; Zhenzhou Yang; Zhixiang Yang
Journal:  Oncol Rep       Date:  2022-09-28       Impact factor: 4.136

Review 7.  Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges.

Authors:  Peng Ye; Xiaoxia Chi; Jong-Ho Cha; Shahang Luo; Guanghui Yang; Xiuwen Yan; Wen-Hao Yang
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.